FDA asked to clarify AI pilot objectives for early-phase clinical trials | RAPS
PhRMA asked FDA to ensure that the pilot incorporates the agency's risk -based approaches to using AI in regulatory decision-making and that AIs are ...
- Topics
- HealthcareRegulation & PolicyGovernment & Public Sector
- Mentions
- FDA
- Tracked via
- “AI Risks”